How to Get NMN/NR (Nicotinamide Mononucleotide/Riboside) in New Hampshire

What NMN and NR Are and Why Clinicians Prescribe Them

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are NAD+ precursors used in clinical practice to support cellular energy metabolism and address measurable NAD+ decline associated with aging. Both compounds convert to NAD+ through distinct enzymatic pathways inside cells, and both are prescribed in New Hampshire as compounded preparations rather than FDA-approved finished drugs.

NAD+ concentrations fall roughly 50% between young adulthood and midlife in human tissue. Yoshino et al. demonstrated in a randomized, double-blind, placebo-controlled trial (N=25 postmenopausal women with prediabetes) that oral NMN 250 mg daily for 10 weeks significantly increased skeletal-muscle NAD+ metabolite levels and improved insulin signaling gene expression compared with placebo 1. That same trial showed NMN improved muscle insulin sensitivity, as measured by the insulin-stimulated glucose disposal rate. Consistent with this, a 2023 randomized crossover trial published in Nature Aging (N=30 recreational runners) found NR supplementation at 1 to 000 mg daily for 21 days increased whole-blood NAD+ by approximately 40% versus baseline 2.

The NAD+ decline mechanism has been studied across multiple tissue types. A 2020 review in Cell Metabolism summarizing preclinical and early clinical evidence concluded that systemic NAD+ repletion with NMN or NR is biologically plausible as a strategy for metabolic support, though large Phase III trials in humans remain ongoing 3. Prescribers in New Hampshire order these agents within a longevity-medicine or metabolic-optimization context, pairing them with objective biomarker monitoring to evaluate response.

Oral bioavailability data support the capsule route. A pharmacokinetic study published in Nature Communications (N=10 healthy adults) confirmed that a single 500 mg oral NMN dose raised plasma NMN levels within 15 minutes and significantly elevated circulating NAD+ metabolites over a 5-hour window 4. Sublingual forms may accelerate absorption further, which is why some compounding pharmacies offer sublingual NMN tablets as an alternative.

The Legal and Regulatory Framework in New Hampshire

New Hampshire permits telehealth prescribing for compounded preparations, including NAD+ precursors, under RSA 329:1-d (the state's telehealth statute) and the New Hampshire Board of Medicine's telehealth rules. No in-person visit is required as long as the prescriber establishes a valid patient-provider relationship through synchronous audio-video consultation.

On the federal side, compounded NMN and NR are prepared by 503A pharmacies under the Federal Food, Drug, and Cosmetic Act Section 503A framework, which allows patient-specific compounding for individual prescriptions. The FDA does not currently list NMN on its list of bulk drug substances that may not be used in compounding; that distinction matters because it means licensed 503A pharmacies can legally prepare NMN for New Hampshire patients 5. NR is similarly compounded through the 503A pathway.

The FDA's compounding oversight framework distinguishes 503A (patient-specific) from 503B (outsourcing facilities producing in bulk). For NMN and NR, 503A is the standard pathway for telehealth prescriptions. Pharmacies shipping to New Hampshire must hold an active New Hampshire Board of Pharmacy out-of-state pharmacy permit in addition to their home-state license.

New Hampshire Medicaid does not cover NMN or NR. The compounds are classified as longevity or NAD precursor supplements in the prescribing context rather than as treatments for a recognized ICD-10 diagnosis covered by insurance. Most patients pay out of pocket; FSA and HSA funds are generally applicable to compounded prescription medications.

How to Get a Prescription in New Hampshire: Step by Step

Getting a prescribed NMN or NR compound in New Hampshire follows a defined clinical sequence. Each step builds on the last, and skipping labs is not an option with a responsible prescriber.

Step 1: Order baseline labs. Before your consultation, you need a comprehensive metabolic panel (CMP), complete blood count (CBC), fasting glucose, hemoglobin A1c (HbA1c), and a lipid panel. Some prescribers also request a baseline NAD+ assay through specialty labs. The American Diabetes Association recommends HbA1c screening for adults over 35 or with risk factors; NMN's insulin-sensitizing effect in the Yoshino trial 1 makes glucose status directly relevant to your clinical workup. The CDC reports that 38% of U.S. adults have prediabetes, many undiagnosed 6, making a baseline HbA1c especially important before starting any metabolically active compound.

Step 2: Complete a telehealth intake. A licensed NH-prescribing clinician reviews your labs, health history, current medications, and goals during a synchronous video visit. This visit typically runs 20 to 40 minutes. The prescriber checks for contraindications (active malignancy, significant hepatic impairment) and screens for drug interactions, particularly with chemotherapy agents that affect NAD+ pathways.

Step 3: Receive and review your prescription. If clinically appropriate, the prescriber writes a patient-specific compounding prescription specifying the compound (NMN or NR), dose (commonly 250 to 500 mg NMN once daily or 300 to 1 to 000 mg NR once daily), dose form, and dispense quantity. The prescription is transmitted electronically to a licensed 503A compounding pharmacy that ships to New Hampshire.

Step 4: Pharmacy preparation and shipment. The 503A pharmacy compounds your preparation, performs quality testing, and ships to your NH address. Standard transit plus compounding lead time is 5 to 10 business days. Temperature-controlled packaging is used if the formulation requires it.

Step 5: Follow-up labs at 60 to 90 days. Responsible prescribers order a repeat CMP, fasting glucose, and HbA1c at 8 to 12 weeks to assess metabolic response. Some also order a follow-up NAD+ assay to confirm target engagement. A 2022 randomized trial (N=66) published in GeroScience found that NMN 300 mg daily for 60 days produced statistically significant increases in NAD+ compared with placebo (P<0.001), along with reductions in drowsiness and improvements in muscle strength scores 7.

Dosing: What New Hampshire Prescribers Typically Order

Standard NMN doses in clinical practice run 250 mg to 500 mg once daily, taken with or without food. NR is typically prescribed at 300 mg to 1 to 000 mg once daily. These ranges reflect the doses used in published human trials and the compounding capacities of licensed 503A pharmacies.

The Yoshino et al. trial used 250 mg NMN daily and demonstrated significant metabolic benefit 1. Higher doses have been studied without significant safety signals in short-term trials. A Phase I safety study (N=10) by Irie et al. published in npj Aging and Mechanisms of Disease confirmed that single oral NMN doses up to 500 mg were safe and well tolerated in healthy men, with no serious adverse events reported 8. Nausea, mild flushing, and transient GI discomfort are the most commonly reported side effects across published trials, occurring in fewer than 10% of participants in most cohorts.

The dose form matters. Oral capsules are the most widely available form from 503A pharmacies and show reliable absorption based on pharmacokinetic data 4. Sublingual tablets or troches may be appropriate for patients with GI absorption concerns. Your prescriber selects the dose form based on your clinical picture.

A 2021 human trial published in Frontiers in Aging (N=80, ages 40 to 65) found that 600 mg NMN daily for 12 weeks significantly reduced biological age markers and improved physical performance scores compared with placebo, with no significant adverse events 9. That study supports the clinical rationale for prescribing NMN at the higher end of the standard range in motivated adult patients.

503A Compounding Pharmacies and Shipping to New Hampshire

No 503A pharmacy can legally ship to New Hampshire without an active NH Board of Pharmacy nonresident pharmacy permit. Patients should confirm their pharmacy holds this permit before accepting a prescription. The New Hampshire Board of Pharmacy maintains a public license verification tool at nh.gov/pharmacy.

503A pharmacies compound NMN and NR in several standard configurations: hard-gelatin capsules, vegetarian capsules, sublingual tablets, and powder sachets. Capsule strengths commonly available include 125 mg, 250 mg, and 500 mg for NMN, and 150 mg, 300 mg, and 500 mg for NR. Custom strengths outside these ranges can be prepared on request.

Quality matters with compounded preparations. The United States Pharmacopeia (USP) Chapter 795 establishes minimum standards for non-sterile compounding, including identity testing, potency verification, and beyond-use dating 10. Ask your pharmacy for a certificate of analysis (COA) confirming the potency and purity of each batch. Reputable 503A pharmacies test every batch through an independent third-party lab and will provide the COA on request.

Shipping to New Hampshire from out-of-state 503A pharmacies typically takes 2 to 5 business days via standard courier after compounding is complete. Compounding lead time adds 2 to 5 additional business days, depending on pharmacy volume. Total time from prescription to delivery averages 5 to 10 business days for first-fill orders.

Who Can Prescribe NMN and NR in New Hampshire

In New Hampshire, prescriptive authority for compounded medications extends to physicians (MD and DO), nurse practitioners (NPs with full practice authority), and physician assistants (PAs) under a collaborating physician agreement. New Hampshire is a full practice authority state for NPs under RSA 326-B:11, meaning a collaborating physician is not required for NPs to prescribe independently.

Telehealth prescribers must hold an active New Hampshire medical or advanced practice license, or must be registered with the NH Secretary of State's office if prescribing from another state under the Interstate Medical Licensure Compact (IMLC). New Hampshire joined the IMLC in 2016, so physicians licensed in any of the 37 IMLC member states can prescribe to NH patients under the compact 11.

The prescribing clinician's job is clinical, not administrative. They assess whether NMN or NR is appropriate for your specific situation, rule out contraindications, select the dose and form, and monitor outcomes. That medical oversight is what separates a prescribed compound from an over-the-counter supplement purchased without guidance.

Lab Monitoring: What to Expect Before and During Treatment

Baseline labs for NMN and NR in New Hampshire follow a standard metabolic panel approach. The core panel is a CMP (14-component metabolic panel covering liver enzymes, kidney function, electrolytes, and glucose), CBC, fasting glucose, HbA1c, and lipid panel. Some prescribers add a NAD+ whole-blood assay to establish a baseline. The Society of Endocrinology does not yet publish specific guidelines for NAD+ precursor monitoring, so prescribers follow internal clinical protocols informed by trial data.

The insulin-sensitizing effects documented in the Yoshino trial 1 are the main reason glucose monitoring at baseline is non-negotiable. Patients with undiagnosed prediabetes or type 2 diabetes need their metabolic management addressed in parallel, as NMN alone is not a substitute for lifestyle modification or approved pharmacotherapy. The ADA's 2024 Standards of Care recommend HbA1c testing at least once per year for all adults with prediabetes 12.

Follow-up labs at 60 to 90 days typically repeat the CMP and fasting glucose at minimum. If your prescriber ordered a baseline NAD+ assay, a follow-up assay confirms target engagement. This is the measurement that distinguishes a responsive patient from a non-responder and guides dose adjustments.

Liver enzyme monitoring within the CMP is appropriate because NAD+ metabolism intersects with SIRT1 and SIRT3 activity, enzymes that regulate hepatic lipid metabolism. No trial has reported clinically significant hepatotoxicity from NMN or NR at standard doses, but baseline and follow-up ALT and AST provide a safety net. A systematic review published in Nutrients (2023) covering 11 randomized controlled trials of NMN and NR found no serious adverse events attributable to either compound across a total of 588 participants 13.

Comparing NMN and NR: Which One Is Right for You

NMN and NR are both NAD+ precursors, but they enter the NAD+ biosynthesis pathway at different points. NMN is one enzymatic step closer to NAD+ than NR is, because NMN is converted directly to NAD+ by NMNAT enzymes, whereas NR must first be phosphorylated to NMN by NRK kinases before that same conversion occurs.

That biochemical difference does not clearly translate to a superior clinical outcome for one over the other in published human trials. The 2022 GeroScience trial 7 used NMN. The Nature Aging crossover trial 2 used NR. Both showed meaningful NAD+ elevation. Head-to-head human RCTs directly comparing NMN versus NR in the same population do not yet exist in the published literature.

Practical differences exist. NMN is more widely available through compounding pharmacies in the dose ranges used in trials (250 to 500 mg). NR has a longer published safety record at the human level, with the Chromadex-sponsored NR safety study (N=12, published in npj Aging) demonstrating tolerability up to 2 to 000 mg daily without serious adverse events 14. Your prescriber weighs your metabolic labs, goals, and any prior supplement history to recommend one over the other.

Cost and Coverage in New Hampshire

NH Medicaid does not cover NMN or NR. Private insurance coverage is essentially nonexistent for these compounds because no NMN or NR product holds FDA approval as a prescription drug. Cash pricing for compounded NMN at 250 to 500 mg daily ranges from $80 to $180 per month depending on the pharmacy and dose form selected. NR at comparable doses runs $70 to $160 per month.

FSA and HSA funds can be applied to compounded prescription medications, including NMN and NR when prescribed by a licensed provider. A prescription is required; over-the-counter NMN supplements are generally not FSA/HSA eligible without a letter of medical necessity. Your telehealth provider can generate this documentation if needed.

Some telehealth platforms bundle the consultation fee, labs, and first-month prescription into a single enrollment price. Ask for itemized pricing so you can compare the cost of consultation, labs, and the compound separately.

Transferring an Existing NMN/NR Prescription to New Hampshire

Patients relocating to New Hampshire who hold an existing NMN or NR compounding prescription from another state can request a prescription transfer if the original prescriber holds an NH license or an IMLC compact license. If they do not, a new consultation with an NH-licensed prescriber is required. This is a brief process, typically a 15-to-20-minute telehealth visit, not a full workup, if recent labs (within 90 days) are available.

The compounding pharmacy itself can be transferred without issue as long as the pharmacy holds a valid NH nonresident pharmacy permit. Most major 503A telehealth pharmacies hold multi-state permits and already ship to New Hampshire.